Cristina Fernandez‐Mendivil
Research Subjects
Research Interests
Cristina Fernandez‐Mendivil has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Hans C. Ebbers
Biogen International GmbH Baar Switzerland
2 shared publications - Jerome Sepin
Center for Health, Policy and Economics, Faculty of Health Sciences and Medicine, University of Lucerne, 6002 Luzern, Switzerland
1 shared publication - Marian Mitroiu
Biogen International GmbH Baar Switzerland
1 shared publication - Niamh M. Kinsella
Biogen Idec, Maidenhead, UK
1 shared publication - Thomas Paul Alfons Debray
Julius Center for Health Sciences and Primary Care University Medical Center Utrecht, Utrecht University Utrecht The Netherlands
1 shared publication Wei Wei
Biogen International GmbH Baar Switzerland
1 shared publication
Latest Publications
- 6 May 2025
- Published by Wiley in Pharmaceutical Statistics
- Vol. 24 (3) , e70008
Applying the Principal Stratum Strategy in Equivalence Trials: A Case Study
The estimand framework, introduced in the ICH E9 (R1) Addendum, provides a structured approach for defining precise research questions in randomised clinical trials. It suggests five strategies for addressing intercurrent events (ICE). This case study examines the principal stratum strategy, highlighting its potential for estimating causal treatment effects in specific subpopulations and the challenges involved. The occurrence of anti‐drug antibodies (ADAs) and their potential clinical impact are important factors in evaluating biosimilars. Typically, analyses focus on subgroups of patients who develop ADAs during the study. However, conducting subgroup analyses based on post‐randomisation variables, such as immunogenicity, can introduce substantial bias into treatment effect estimates and is therefore methodologically not optimal. The principal stratum strategy provides a statistical pathway for estimating treatment effects in subpopulations that cannot be anticipated at baseline. By leveraging counterfactuals to assess treatment outcomes, with and without the incidence of intercurrent events (ICEs), this approach can be implemented through a missing data perspective. We demonstrate the implementation of the principal stratum strategy in a phase 3 equivalence trial of a biosimilar for the treatment of rheumatoid arthritis. Using a multiple imputation approach, we leverage longitudinal measurements to create analysis datasets for subpopulations who develop ADAs as ICE. Our results highlight the principal stratum strategy's potential and challenges, emphasising its reliance on unobserved ICE states and the need for complex and rigorous modelling. This study contributes to a nuanced understanding and practical implementation of the principal stratum strategy within the ICH E9 (R1) framework.
- 6 May 2025
- Published by Wiley in Pharmaceutical Statistics
- Vol. 24 (3) , e70008
Applying the Principal Stratum Strategy in Equivalence Trials: A Case Study
The estimand framework, introduced in the ICH E9 (R1) Addendum, provides a structured approach for defining precise research questions in randomised clinical trials. It suggests five strategies for addressing intercurrent events (ICE). This case study examines the principal stratum strategy, highlighting its potential for estimating causal treatment effects in specific subpopulations and the challenges involved. The occurrence of anti‐drug antibodies (ADAs) and their potential clinical impact are important factors in evaluating biosimilars. Typically, analyses focus on subgroups of patients who develop ADAs during the study. However, conducting subgroup analyses based on post‐randomisation variables, such as immunogenicity, can introduce substantial bias into treatment effect estimates and is therefore methodologically not optimal. The principal stratum strategy provides a statistical pathway for estimating treatment effects in subpopulations that cannot be anticipated at baseline. By leveraging counterfactuals to assess treatment outcomes, with and without the incidence of intercurrent events (ICEs), this approach can be implemented through a missing data perspective. We demonstrate the implementation of the principal stratum strategy in a phase 3 equivalence trial of a biosimilar for the treatment of rheumatoid arthritis. Using a multiple imputation approach, we leverage longitudinal measurements to create analysis datasets for subpopulations who develop ADAs as ICE. Our results highlight the principal stratum strategy's potential and challenges, emphasising its reliance on unobserved ICE states and the need for complex and rigorous modelling. This study contributes to a nuanced understanding and practical implementation of the principal stratum strategy within the ICH E9 (R1) framework.
- Open Access
- 29 January 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (5) , 1122-1131
A Retrospective Analysis of the Potential Impact of Differences in Aggregates on Clinical Immunogenicity of Biosimilars and their Reference Products
Aggregates, in particular high molecular weight species (HMWs), have been linked to increased immunogenicity. The current understanding on the impact of HMWs is mainly based on in vitro and nonclinical studies and there are only limited data available associating differences in HMWs in marketed monoclonal antibodies (mAbs) to clinical outcomes. Biosimilars offer a unique opportunity to study the potential association between quality parameters and clinical outcomes. We performed a retrospective evaluation to investigate the association between HMW content and reported antidrug‐antibody (ADA) incidence in 30 full‐length biosimilar mAbs approved in the European Union and the United States. Information for HMW content and ADA incidence were collected from publicly available sources. Differences in HMW content between biosimilars and their reference products (RPs) ranged from −0.75 to 1.65% with slightly higher differences observed in antineoplastic products as compared with immunosuppressant products. The difference in the ADA incidence between the RP and the biosimilar for the programs studied ranged from −11.0 to 18.5%. No association was observed between differences in HMW content and reported ADA incidence, in neither phase I nor phase III studies. Our results show that the limited differences in the content of HMWs between marketed biosimilars and reference mAbs were not associated with differences in reported immunogenicity, determined as incidence of ADAs and neutralizing ADAs in comparative clinical studies.
- 29 January 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (5) , 1122-1131
Open AccessA Retrospective Analysis of the Potential Impact of Differences in Aggregates on Clinical Immunogenicity of Biosimilars and their Reference Products
Aggregates, in particular high molecular weight species (HMWs), have been linked to increased immunogenicity. The current understanding on the impact of HMWs is mainly based on in vitro and nonclinical studies and there are only limited data available associating differences in HMWs in marketed monoclonal antibodies (mAbs) to clinical outcomes. Biosimilars offer a unique opportunity to study the potential association between quality parameters and clinical outcomes. We performed a retrospective evaluation to investigate the association between HMW content and reported antidrug‐antibody (ADA) incidence in 30 full‐length biosimilar mAbs approved in the European Union and the United States. Information for HMW content and ADA incidence were collected from publicly available sources. Differences in HMW content between biosimilars and their reference products (RPs) ranged from −0.75 to 1.65% with slightly higher differences observed in antineoplastic products as compared with immunosuppressant products. The difference in the ADA incidence between the RP and the biosimilar for the programs studied ranged from −11.0 to 18.5%. No association was observed between differences in HMW content and reported ADA incidence, in neither phase I nor phase III studies. Our results show that the limited differences in the content of HMWs between marketed biosimilars and reference mAbs were not associated with differences in reported immunogenicity, determined as incidence of ADAs and neutralizing ADAs in comparative clinical studies.